Navigation Links
Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital
Date:12/15/2009

NEW HAVEN, Conn., Dec. 15 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel drugs for the treatment of serious multi-drug-resistant infections announced today it has entered into a collaborative research agreement with Massachusetts General Hospital (MGH).

Under the science plan for the collaboration, Dr. David Hooper of MGH will evaluate Rib-X's novel fluoroquinolone, delafloxacin, in an established animal model to determine resistance development and to validate the activity and mechanism of action of delafloxacin against microorganisms such as methicillin-resistant Staphylococcus aureus (MRSA).

"Treating infections that are resistant to the antibiotics currently available to us has become increasingly challenging," Dr. Hooper said. "We are interested to learn more about the unusual properties of this specific drug relative to other members of its class and its potential effect on controlling difficult and dangerous infections."

Delafloxacin, which is ready to enter Phase 3 clinical trials, is a novel, broad-spectrum, next-generation fluoroquinolone, that has demonstrated better activity than other quinolones against Gram-positive bacteria, including isolates of MRSA that are quinolone-resistant.

"The opportunity to work with Dr. David Hooper on the in vivo mechanism of action of delafloxacin is a very important extension of the research we have done here at Rib-X," said Susan Froshauer, Ph.D., Rib-X's President and CEO. "Dr. Hooper is a well-known expert on fluoroquinolones and this collaboration will demonstrate the potential for delafloxacin to take its place in the arsenal of drugs for battling recalcitrant quinolone-resistant infections."

Rib-X previously announced positive results from a Phase 2 trial utilizing the IV formulation of delafloxacin in complicated skin and skin structure infections (cSS
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Rib-X Pharmaceuticals Expands License Agreement with Yale University on New Ribosome Technology
2. Rib-X Pharmaceuticals, Inc. Co-Founder, Thomas A. Steitz, Ph.D., Awarded the 2009 Nobel Prize in Chemistry
3. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
4. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
5. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
6. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
7. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
8. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
9. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
10. Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
11. Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 The report based on ... Share, Growth and Forecast, 2007 - 2017," elaborated by ... 20.8 billion in 2012 and is further expected to ... CAGR of 7.3% from 2012 to 2017. ... purposes, especially to prevent chronic diseases that may occur ...
(Date:9/30/2014)... , September 30, 2014 ... the CSF (Cerebrospinal Fluid) backflow of the Eldor spinal ... of the single hole pencil point spinal needles of ... Braun. Spinal anesthesia is an excellent type ... Orthopedics, Urology, General Anesthesia, etc. It is ...
(Date:9/30/2014)...   Acutus Medical, Inc. (ACM), a ... Cardiac Chamber Imaging and Dipole Density Mapping system to ... complex cardiac arrhythmias, including atrial fibrillation, announced it has ... imaging/mapping system as well as bring to market a ... to complete work on the AcQMap TM High ...
Breaking Medicine Technology:Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 2Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 3
... When it comes to breast cancer, a physician,s ability ... of treatment depends on the quality of information revealed through ... the most advanced technology in breast cancer detection with positron ... PEM scanners in the Chicagoland area. Essentially, PEM ...
... BETHLEHEM, Pa., Nov. 1, 2011 Saladax Biomedical, Inc., ... assays to achieve the promise of personalized medicine for ... M.D., has accepted to chair the company,s scientific advisory ... as chief of the Division of Hematology/Oncology in the ...
Cached Medicine Technology:Palos Offers New Technology in the Fight Against Breast Cancer 2Saladax Biomedical, Inc. Names Edward Chu, M.D., Chair of the Company's Scientific Advisory Board 2Saladax Biomedical, Inc. Names Edward Chu, M.D., Chair of the Company's Scientific Advisory Board 3
(Date:9/30/2014)... Ohio (PRWEB) September 30, 2014 Life ... which provides CHL access to Life Length’s proprietary Telomere ... advanced and comprehensive telomere test on the market today, ... reports the percentage of short telomeres, providing the most ... Vice Chairman of the Department of Cell Biology at ...
(Date:9/30/2014)... Market Research Report on Global and ... in-depth market survey on Global and Chinese Cialis ... of Cialis including its classification, application and manufacturing ... top manufacturers of Cialis listing their product specification, ... The report further analyzes quantitatively 2009-2014 global and ...
(Date:9/30/2014)... 30, 2014 Catalent Pharma Solutions ... delivery technologies and development solutions for drugs, biologics ... agenda for the 25th Annual CPhI Worldwide Exhibition ... 6th to 9th. , Catalent is showcasing a ... during the show, including its facilities in China ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 ADOAMNI, ... first “crowdfunding” campaign through GoFundMe. The campaign, which surpassed ... for a portion of the funds necessary to convert ... for the Stockton Unified School District (SUSD). The campaign ... provide a portion of the funds necessary for the ...
(Date:9/30/2014)... The American Parkinson Disease ... supporting seven Research grants to junior investigators pursuing ... support post-doctoral scientists whose research training holds promise ... and treatment of Parkinson’s disease, and eight Centers ... medical centers across the country intended to strengthen ...
Breaking Medicine News(10 mins):Health News:Life Length® Announces New Partnership with Cleveland HeartLab® to Offer Telomere Technology in North America 2Health News:Life Length® Announces New Partnership with Cleveland HeartLab® to Offer Telomere Technology in North America 3Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4Health News:Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition 2Health News:Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition 3Health News:ADOMANI Raises More Than 100,000 Dollars Through GoFundMe to Convert a School Bus 2Health News:ADOMANI Raises More Than 100,000 Dollars Through GoFundMe to Convert a School Bus 3Health News:The American Parkinson Disease Association Awards $1.1 million in Research Grants and Continues to Lead the Way to Ease the Burden – Find the Cure for Parkinson’s Disease 2Health News:The American Parkinson Disease Association Awards $1.1 million in Research Grants and Continues to Lead the Way to Ease the Burden – Find the Cure for Parkinson’s Disease 3Health News:The American Parkinson Disease Association Awards $1.1 million in Research Grants and Continues to Lead the Way to Ease the Burden – Find the Cure for Parkinson’s Disease 4
... reason for hope, experts say , , FRIDAY, Sept. 28 ... to treat the autoimmune disease lupus is building up ... an upbeat tone, researchers from across the United States ... Research Institute (LRI) of the improving outlook for patients ...
... The Branded Pharmaceutical,Association (BPA) represents specialty manufacturers, ... of the BPA produce,market or distribute Legacy ... drugs, with a history of safety and ... these products are manufactured in FDA licensed ...
... YORK, Sept. 28 According to the ... nearly one million Latinos received,physician-administered aesthetic procedures ... Flor Mayoral, a board certified,dermatologist in Miami, ... it is important that women make informed ...
... Senior Living,Inc. (NYSE: SRZ ) today announced ... being conducted by the Special Independent Committee of ... Sarbanes-Oxley,Section 404 internal control review efforts and provided ... Investigation As previously disclosed, in December 2006, ...
... Calif., Sept. 28 TJ Enterprises, LLC,announced ... a safe,alternative in the treatment of baby ... This comes after the U.S. Food and ... unopened,retail samples of a non-homeopathic gripe water, ...
... Care,Management Association (PCMA) released the following statement today,supporting ... the,House Energy and Commerce Subcommittee on Health: ... earlier,this week that would fix the flawed Average ... Reduction Act. "PCMA supports the decision to ...
Cached Medicine News:Health News:Better Lupus Treatments on the Horizon 2Health News:Better Lupus Treatments on the Horizon 3Health News:Better Lupus Treatments on the Horizon 4Health News:The Branded Pharmaceutical Association Comments on Hydrocodone 2Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 2Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 3Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 4Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 5Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 6Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 7Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 8Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 9Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 10Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 11Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 12Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 13Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 14Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 15Health News:After Infant Gripe Water Recall Scare, Homeopathic Medicine Offers Safe Alternative 2
The VPAP III ST is a complete system solution for SDB, providing comfortable and effective bilevel treatment with additional treatment modes. The VPAP III ST is an effective business solution for cli...
The GoodKnight® 425 Bi-Level® device is suitable for travel and includes features such as automatic altitude compensation, optional cigarette lighter adapter and portable battery pack...
... The BiPAP Pro with Bi-Flex bi-level ... time that the BiPAP Pro takes to ... includes Digital Auto-Trak Sensitivity™ which automatically triggers ... expiratory pressures based on the patients breathing ...
... Electrophoresis System (PGGE) is designed to ... density lipoproteins (LDL) and high density ... using nondenaturing pore gradient gel electrophoresis. ... short DNA sequencing runs. Temperature control ...
Medicine Products: